Urokinase receptor: Difference between revisions

← Older edit

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

Michal Harel, Alexander Berchansky

@@ Line 1: / Line 1: @@
-<StructureSection load='2i9b' size='340' side='right' caption='Caption for this structure(PDB code [[2i9b]])' scene=''>
+<StructureSection load='2i9b' size='340' side='right' caption='Human uPAR (grey) complex with glycosylated uPA (magenta) and sulfate (PDB code [[2i9b]])' scene='10/1041521/Cv/1'>
 == Function ==
-'''Urokinase receptor''' or '''Urokinase plasminogen activator surface receptor''' or '''CD87''' (uPAR) plays an important role in migration of T cells<ref>PMID:8283034</ref>.  uPAR is a GPI-anchored membrane protein.  It triggers cell signalling and regulates gene expression within the cell
+'''Urokinase receptor''' or '''Urokinase plasminogen activator surface receptor''' or '''CD87''' (uPAR) plays an important role in migration of T cells<ref>PMID:8283034</ref>.  uPAR is a GPI-anchored membrane protein.  It triggers cell signalling and regulates gene expression within the cell.  The invasive potential of uPAR expressing tumor cells is modulated by interaction with
+urokinase plasminogen activator (uPA)<ref>PMID:1659573</ref>.
 == Disease ==
-uPAR can control the shift between tutor dormancy and proliferation to form metastasis<ref>PMID:28839232</ref>
+uPAR can control the shift between tumor dormancy and proliferation to form metastasis<ref>PMID:28839232</ref>
 == Relevance ==
-Elevated levels of soluble uPAR are associated with kidney disease<ref>PMID:26539835</ref>.  uPAR which is expressed at high levels in malignant tutors is unattractive target for treatment of cancer<ref>PMID:35303878</ref>.  uPAR activity in cancer cells may counteract the activity of anticancer drugs<ref>PMID:26283964</ref>.
+Elevated levels of soluble uPAR are associated with kidney disease<ref>PMID:26539835</ref>.  uPAR which is expressed at high levels in malignant tumors is an attractive target for treatment of cancer<ref>PMID:35303878</ref>.  uPAR activity in cancer cells may counteract the activity of anticancer drugs<ref>PMID:26283964</ref>.
+==Structural highlights==
-== Structural highlights ==
+The binding of uPAR and urokinase-type plasminogen activator (uPA) is mediated by hydrophobic numerous interactions. <scene name='10/1041521/Cv/2'>In particular the interactions between uPA residue Trp30 and uPAR numerous hydrophobic residues</scene><ref>PMID:16979660</ref>.
-This is a sample scene created with SAT to <scene name="/12/3456/Sample/1">color</scene> by Group, and another to make <scene name="/12/3456/Sample/2">a transparent representation</scene> of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.
+==3D structures of urokinase receptor==
-</StructureSection>
+[[Urokinase plasminogen activator surface receptor 3D structures]]
 == References ==
 <references/>
+</StructureSection>
+[[Category:Topic Page]]